The Valley Desk

ArticleTrialsPublished

Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Drexel University College of Medicine, Johnson & Johnson, Perelman School of Medicine, with Drexel University, University of Pennsylvania linked by the institution reference. Affiliation source

Publication record

Type
Article
Venue
Trials
Published
Subject terms
Humans; Arthritis, Psoriatic; Tumor Necrosis Factor-alpha; Antirheumatic Agents; Antibodies, Monoclonal; Treatment Outcome; Longitudinal Studies; Prospective Studies; Time Factors; Multicenter Studies as Topic; Clinical Trials, Phase III as Topic; Drug Substitution
PubMed ID
40102973
PubMed Central ID
PMC11921613
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal